Emergent Biosolutions
EBS
198 hedge funds and large institutions have $1.5B invested in Emergent Biosolutions in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 80 increasing their positions, 54 reducing their positions, and 12 closing their positions.
175% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 12
49% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $2.08M
48% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 54
25% more capital invested
Capital invested by funds: $1.2B → $1.5B (+$301M)
9% more funds holding
Funds holding: 181 → 198 (+17)
3.05% more ownership
Funds ownership: 86.95% → 90% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$12M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.95M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$5.57M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.32M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$4.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TA
Teachers Advisors
New York
|
-$9.99M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$7.71M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$4.65M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.37M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$3.11M |
EBS Hedge Fund Activity: Q3 2017 in Review
198 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2017, worth a combined $1.5B — up 25% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new EBS positions and 12 closed out — a net gain of 21 holders — while 80 added to existing stakes and 54 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $12M. The largest seller was Teachers Advisors, cutting an estimated $9.99M.
- 198 institutional investors held Emergent Biosolutions (EBS) as of Q3 2017, up from 181 in Q2 2017.
- Funds reported $1.5B of Emergent Biosolutions stock for Q3 2017, up 25% quarter-over-quarter.
- 33 funds opened new Emergent Biosolutions positions in Q3 2017 and 12 closed out, a net change of +21 holders.
- The largest Emergent Biosolutions buyer in Q3 2017 was Renaissance Technologies, an estimated $12M added.
- The largest Emergent Biosolutions seller in Q3 2017 was Teachers Advisors, an estimated $9.99M sold.
Based on aggregated 13F filings for Q3 2017.